FrancophonIA/ELRC3.0 huggingface dataset:
English: The active substance in Verkazia, ciclosporin, blocks cells of the immune system (the body's natural defences) that are involved in the processes that cause the allergic reaction and inflammation in patients with VKC.
Estonian: Verkazia toimeaine tsüklosporiin blokeerib immuunsüsteemi (organismi looduslik kaitsemehhanism) rakud, mis on seotud kevadkeratokonjunktiviidiga patsientidel allergilist reaktsiooni ja põletikku tekitavate protsessidega.
English: For the full list of all side effects and restrictions with Verkazia, see the package leaflet.
Estonian: Verkazia kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Verkazia can only be obtained with a prescription and treatment must be started by a healthcare professional qualified in ophthalmology (eye medicine).
Estonian: Verkazia on retseptiravim ja ravi peab alustama oftalmoloog (silmaarst).
English: This is a summary of the European public assessment report (EPAR) for Verkazia.
Estonian: See on ravimi Verkazia Euroopa avaliku hindamisaruande kokkuvõte.
English: What benefits of Verkazia have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Verkazia kasulikkus?
English: The most common side effects with Verkazia are eye pain and itching, which may affect around 1 in 10 people.
Estonian: Verkazia kõige sagedamad kõrvalnähud (võivad esineda umbes 1 patsiendil 10st) on silmavalu jasügelus.
English: How does Verkazia work?
Estonian: Kuidas Verkazia toimib?
English: Symptoms such as itching, fluid or mucous discharge and light sensitivity also improved in patients treated with Verkazia to a greater extent than with the dummy treatment.
Estonian: Verkazia leevendas platseebost paremini ka selliseid sümptomeid nagu silmade sügelus, pisaravool või limaeritus ning valgustundlikkus.
English: This summary was last updated in 07-2018.
Estonian: Verkazia EMA/467989/2018
English: Starting doses are between 0.1 and 0.3 mg per kg bodyweight daily.
Estonian: Algannus on 0,1 kuni 0,3 mg kehakaalu kg kohta ööpäevas.
English: What measures are being taken to ensure the safe and effective use of Tacforius?
Estonian: Mis meetmed võetakse, et tagada Tacforiuse ohutu ja efektiivne kasutamine?
English: The full EPAR for Tacforius can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Tacforiuse kohta on ameti veebilehel ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: As for every medicine, the company provided studies on the quality of Tacforius.
Estonian: Nagu iga ravimi korral, esitas ettevõte uuringud Tacforiuse kvaliteedi kohta.
English: Tacforius should be taken once daily with water, on an empty stomach.
Estonian: Tacforius tuleb koos veega sisse võtta ainult üks kord ööpäevas tühja kõhuga.
English: The prolonged-release capsules allow tacrolimus to be released slowly from the capsule over several hours so that it needs to be taken only once a day.
Estonian: Toimeainet prolongeeritult vabastavad kapslid võimaldavad takroliimusel vabaneda kapslist aeglaselt mitme tunni jooksul, mistõttu peab seda võtma ainult üks kord ööpäevas.
English: What is Tacforius and what is it used for?
Estonian: Mis on Tacforius ja milleks seda kasutatakse?
English: Other information about Tacforius
Estonian: Muu teave Tacforiuse kohta
English: This means that Tacforius contains the same active substance and works in the same way as a ‘reference medicine' already authorised in the European Union (EU) called Advagraf.
Estonian: See tähendab, et Tacforius sisaldab sama toimeainet ja toimib samal viisil kui võrdlusravim Advagraf, millel juba on Euroopa Liidus müügiluba.
English: Tacforius tacrolimus
Estonian: Tacforius takroliimus
English: It is not intended to provide practical advice on how to use Tacforius.
Estonian: Hindamisaruandes ei anta Tacforiuse kasutamise praktilisi nõuandeid.
English: The European Medicines Agency concluded that, in accordance with EU requirements, Tacforius has been shown to have comparable quality and to be bioequivalent to Advagraf.
Estonian: Euroopa Ravimiamet järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Tacforiuse võrreldav kvaliteet ja bioekvivalentsus ravimiga Advagraf.
English: Tacforius can also be used to treat organ rejection in adult patients when other immunosuppressive medicines (medicines that reduce the activity of the immune system) are not effective.
Estonian: Tacforiust saab kasutada ka elundi äratõukereaktsiooni raviks täiskasvanud patsientidel, kui teised immunosupressiivsed ravimid (immuunsüsteemi aktiivsust vähendavad ravimid) ei ole efektiivsed.
English: Because Tacforius is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Estonian: Et Tacforius on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse tema kasulikkust ja riske samaks mis võrdlusravimil.
English: Studies on the benefits and risks of the active substance in the approved uses have already been carried out with the reference medicine, Advagraf, and do not need to be repeated for Tacforius.
Estonian: Võrdlusravimiga Advagraf on juba tehtud toimeaine heakskiidetud kasutusviiside kasulikkuse ja riski uuringud ning neid ei ole vaja ravimiga Tacforius korrata.
English: The doses are then adjusted according to the patient's response and the medicine's blood levels.
Estonian: Seejärel kohandatakse annust vastavalt patsiendi ravivastusele ja ravimi kontsentratsioonile veres.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Tacforius have been included in the summary of product characteristics and the package leaflet.
Estonian: Tacforiusi ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Why is Tacforius approved?
Estonian: Miks Tacforius heaks kiideti?
English: Therefore, the Agency's view was that, as for Advagraf, the benefit outweighs the identified risk.
Estonian: Seetõttu on ravimiamet arvamusel, et nagu ka Advagrafi korral, ületab ravimi Tacforius kasulikkus sellega kaasnevad riskid.
English: The Agency recommended that Tacforius be approved for use in the EU.
Estonian: Ravimiamet soovitas anda ravimile Tacforius Euroopa Liidus kasutamiseks müügiloa.
English: This is a summary of the European public assessment report (EPAR) for Tacforius.
Estonian: See on ravimi Tacforius Euroopa avaliku hindamisaruande kokkuvõte.
English: For practical information about using Tacforius, patients should read the package leaflet or contact their doctor or pharmacist.
Estonian: Kui vajate Tacforiuse kasutamise praktilisi nõuandeid, lugege pakendi infolehte või pöörduge oma arsti või apteekri poole.
English: For more information about treatment with Tacforius, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Tacforiusega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Tacforius contains the active substance tacrolimus and is a ‘generic medicine'.
Estonian: Tacforius sisaldab toimeainena takroliimust ja see on geneeriline ravim.
English: Doses of Tacforius are calculated on the basis of the patient's weight and the type of transplant the patient has had.
Estonian: Tacforiuse annus arvutatakse patsiendi kehakaalu ja patsiendi siiriku tüübi põhjal.
English: Tacrolimus reduces the activity of cells in the immune system, called T-cells, that are primarily involved in attacking the transplanted organ (organ rejection).
Estonian: Takroliimus vähendab siiratud elundi ründamisel (elundi äratõukereaktsioonis) peamiselt osalevate immuunsüsteemi rakkude, T-rakkude aktiivsust.
English: Tacforius is used for the long-term treatment of adult patients who have had a kidney or liver transplant, to prevent rejection (when the immune system attacks the transplanted organ).
Estonian: Tacforiust kasutatakse neeru- või maksasiirikuga täiskasvanud patsientide pikaajaliseks raviks äratõukereaktsiooni (kui immuunsüsteem ründab siiratud elundit) ennetamiseks.
English: What are the benefits and risks of Tacforius?
Estonian: Milles seisneb Tacforiuse kasulikkus ja mis riskid ravimiga kaasnevad?
English: Tacforius is available as prolonged-release capsules containing tacrolimus.
Estonian: Tacforius tarnitakse takroliimust prolongeeritult vabastavate kapslitena.
English: Tacrolimus, the active substance in Tacforius, is an immunosuppressive medicine.
Estonian: Tacforiuse toimeaine takroliimus on immunosupressant.
English: How does Tacforius work?
Estonian: Kuidas Tacforius toimib?
English: Only doctors experienced in immunosuppressive medicines and in the management of transplant patients should prescribe it and make changes to immunosuppressive treatment.
Estonian: Immunosupressiivset ravi tohivad määrata ja muuta ainult immunosupressiivsete ravimite kasutamises ja siirikuga patsientide ravis kogenud arstid.
English: How is Tacforius used?
Estonian: Kuidas Tacforiust kasutatakse?
English: How has Tacforius been studied?
Estonian: Kuidas Tacforiust uuriti?
English: Tacforius can only be obtained with a prescription.
Estonian: Tacforius on retseptiravim.
English: Ultomiris (ravulizumab)
Estonian: Ultomiris (ravulisumaab)
English: What measures are being taken to ensure the safe and effective use of Ultomiris?
Estonian: Mis meetmed võetakse, et tagada Ultomirise ohutu ja efektiivne kasutamine?
English: Further information on Ultomiris can be found on the Agency's website: ema.europa.eu/medicines/human/EPAR/Ultomiris.
Estonian: Lisateave Ultomirise kohta on ameti veebilehel: ema.europa.eu/medicines/human/EPAR/Ultomiris.
English: Patients should take antibiotics for 2 weeks after they have been vaccinated.
Estonian: Patsiendid peavad antibiootikume võtma 2 nädala jooksul pärast vaktsineerimist.
English: This is a life-long treatment.
Estonian: Ravi kestab kogu elu.
English: Other information about Ultomiris
Estonian: Muu teave Ultomirise kohta
English: The European Medicines Agency also noted that Ultomiris has a more convenient treatment schedule (with one infusion every 8 weeks instead of every 2 weeks).
Estonian: Euroopa Ravimiamet märkis ka, et Ultomirisel on mugavam manustamiskava (üks infusioon iga 8, mitte iga 2 nädala järel).
English: In addition, around half of the patients in both groups had achieved normal blood levels of the enzyme LDH.
Estonian: Lisaks oli ligikaudu pool mõlema rühma patsientidest saavutanud ensüümi LDH normaalse sisalduse veres.
English: The change in blood levels of LDH after 6 months of treatment was similar in the 2 groups.
Estonian: Vere LDH-sisalduse muutus pärast 6-kuulist ravi oli mõlemas rühmas sarnane.
English: The Agency therefore decided that Ultomiris' benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Utomirise kasulikkus on suurem kui sellega kaasnevad riskid ja et ravimi kasutamise võib ELis heaks kiita.
English: As for all medicines, data on the use of Ultomiris are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, teostatakse Ultomirise kasutamise kohta pidevat järelevalvet.
English: What is Ultomiris and what is it used for?
Estonian: Mis on Ultomiris ja milleks seda kasutatakse?
English: For more information about using Ultomiris, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Ultomirise kasutamise kohta vt pakendi infolehest või konsulteeri oma arsti või apteekriga.
English: It must also not be used in patients who have not been vaccinated against this infection unless they are taking antibiotics to reduce the risk of infection.
Estonian: Seda ei tohi kasutada ka patsiendid, keda ei ole selle infektsiooni vastu vaktsineeritud, v.a kui nad võtavad infektsiooniriski vähendamiseks antibiootikume.
English: Patients receive an initial dose (called loading dose) and then a maintenance dose once every 8 weeks, starting 2 weeks after the loading dose.
Estonian: Patsiendid saavad esialgse annuse (küllastusannuse) ja seejärel säilitusannuse iga 8 nädala järel, esimese säilitusannuse 2 nädalat pärast küllastusannust.
English: Side effects reported with Ultomiris are carefully evaluated and any necessary action taken to protect patients.
Estonian: Ultomirise kõrvaltoimeid hinnatakse hoolikalt ja patsientide kaitseks rakendatakse vajalikke meetmeid.
English: The company that markets Ultomiris will ensure that the medicine is only made available to patients when healthcare professionals have made a written declaration that they have been vaccinated or are receiving antibiotic treatment to prevent meningococcal disease.
Estonian: Ultomirise turustaja tagab, et ravim tehakse patsientidele kättesaadavaks üksnes siis, kui tervishoiutöötajad on esitanud kirjaliku deklaratsiooni, et patsiendid on vaktsineeritud või saavad antibiootikumravi, et vältida meningokokkhaigust.
English: What are the risks associated with Ultomiris?
Estonian: Mis riskid Ultomirisega kaasnevad?
English: After 6 months of treatment, similar benefits were seen in both groups, with two-thirds or more of patients (74% given Ultomiris and 66% given eculizumab) not needing red blood cell transfusions.
Estonian: Pärast 6-kuulist ravi täheldati mõlemas uuringurühmas sarnast kasulikkust: vähemalt kaks kolmandikku patsiente (Ultomirise rühmas 74% ja ekulisumaabi rühmas 66%) ei vajanud erütrotsüütide ülekandeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Ultomiris have also been included in the summary of product characteristics and the package leaflet.
Estonian: Ultomirise ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: The most common side effects with Ultomiris (which may affect more than 1 in 10 people) are upper respiratory tract infection (nose and throat infection), nasopharyngitis (inflammation of the nose and throat) and headache.
Estonian: Ultomirise kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 10st) on ülemiste hingamisteede infektsioon (nina- ja kurguinfektsioon), nasofarüngiit (nina- ja kurgupõletik) ning peavalu.
English: By attaching to the C5 protein, the medicine blocks its effect and thereby reduces the destruction of red blood cells.
Estonian: C5-valguga seondudes blokeerib ravim selle toime ja vähendab seega erütrotsüütide lagunemist.
English: For the full list of side effects and restrictions with Ultomiris, see the package leaflet.
Estonian: Ultomirise kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Because patients treated with Ultomiris are more prone to infections, including severe meningococcal disease, Ultomiris must not be used in patients who have an ongoing meningococcal infection.
Estonian: Et Ultomirisega ravitud patsientide infektsioonirisk on suurem (sh raske menigokokkhaiguse risk), ei tohi Ultomirist kasutada patsientidel, kellel on aktiivne meningokokkinfektsioon.
English: The company will also provide prescribers and patients with information on the safety of the medicine, and will send reminders to prescribers and pharmacists to check if re-vaccination is needed for patients taking Ultomiris.
Estonian: Turustaja annab ka ravi määravatele meditsiinitöötajatele ja patsientidele ravimi ohutusteabe ning saadab ravi määravatele meditsiinitöötajatele ja apteekritele meeldetuletuse kontrollida, kas Ultomirist kasutavaid patsiente on vaja kordusvaktsineerida.
English: In addition, none of the patients treated with Ultomiris had a flare-up of symptoms during this time, in comparison to 5 of those continuing with eculizumab.
Estonian: Peale selle ei ägenenud sümptomid selle aja jooksul ühelgi Ultomirisega ravitud patsiendil võrreldes 5 patsiendiga, kes jätkasid ravi ekulisumaabiga.
English: In the second study in 195 patients with PNH who did not have symptoms after at least 6 months of treatment with eculizumab, patients either continued treatment with eculizumab or switched to Ultomiris.
Estonian: Teises uuringus, kus osales 195 paroksüsmaalse öise hemoglobinuuriaga patsienti, kellel ei esinenud pärast ekulisumaabiravi vähemalt 6 kuu jooksul sümptomeid, jätkasid patsiendid ravi kas ekulisumaabiga või vahetasid ravimiks Ultomirise.
English: As for its safety, Ultomiris has similar side effects to eculizumab.
Estonian: Ohutuse poolest sarnanevad Ultomirise kõrvalnähud ekulisumaabi omadega.
English: How is Ultomiris used?
Estonian: Kuidas Ultomirist kasutatakse?
English: Patients will also be given a special card that explains the symptoms of meningococcal infection, instructing patients to seek medical care immediately if they experience them.
Estonian: Patsientidele antakse eriline hoiatuskaart, kus kirjeldatakse meningokokkinfektsiooni sümptomeid ja selgitatakse, et nende tekkimisel tuleb otsekohe pöörduda arsti poole.
English: The most serious side effect is meningococcal infection, a bacterial infection caused by Neisseria meningitidis that can cause meningitis and blood poisoning.
Estonian: Kõige raskem kõrvalnäht on meningokokkinfektsioon ehk bakteri Neisseria meningitidis põhjustatud bakterinfektsioon, mis võib põhjustada meningiiti (ajukelmepõletik) ja sepsist (veremürgistus).
English: In the first study, 246 patients with PNH who previously had not been treated with a medicine blocking the complement system, such as eculizumab, received either Ultomiris or eculizumab.
Estonian: Esimeses uuringus osales 246 öise hemoglobinuuriaga patsienti, keda ei olnud varem ravitud komplemendisüsteemi blokeeriva ravimiga (nt ekulisumaabiga) ja kes said kas Ultomirist või ekulisumaabi.
English: Ultomiris is given as an infusion (drip) into a vein and the recommended dose depends on the patient's bodyweight.
Estonian: Ultomirist manustatakse veeniinfusioonina ja soovitatav annus sõltub patsiendi kehamassist.
English: How does Ultomiris work?
Estonian: Kuidas Ultomiris toimib?
English: What benefits of Ultomiris have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Ultomirise kasulikkus?
English: PNH is a potentially life-threatening disease in which there is excessive breakdown of red blood cells, leading to problems such as anaemia (low red blood cell counts), kidney problems and blood clots in the blood vessels.
Estonian: Paroksüsmaalne öine hemoglobinuuria on potentsiaalselt eluohtlik haigus, mille korral esineb erütrotsüütide (vere punaliblede) liigne lagunemine, mis põhjustab selliseid probleeme nagu aneemia (erütrotsüütide vähesus), neeruprobleemid ja trombide teke veresoontes.
English: Ultomiris was shown in 2 studies to be as effective as eculizumab in reducing the breakdown of red blood cells and avoiding the need for transfusions in patients with PNH.
Estonian: 2 uuringus tõendati, et Ultomiris oli sama efektiivne kui ekulisumaab erütrotsüütide lagunemise vähendamisel ja vereülekannete vajaduse vältimisel paroksüsmaalse öise hemoglobinuuriaga patsientidel.
English: Ultomiris is used in patients who have symptoms of the disease as well as in patients who have stable blood levels of the enzyme lactate dehydrogenase (LDH), which gives an indication of how many red blood cells are being broken down.
Estonian: Ultomirist kasutatakse haiguse sümptomitega patsientidel ja patsientidel, kellel on ensüümi laktaatdehüdrogenaasi (LDH) stabiilne sisaldus veres.
English: An overview of Ultomiris and why it is authorised in the EU
Estonian: Ülevaade ravimist Ultomiris ja ELis müügiloa väljastamise põhjendus
English: The active substance contained in Ultomiris, ravulizumab, is a monoclonal antibody (a type of protein) designed to attach to the C5 protein, which is part of the complement system.
Estonian: Ultomirise toimeaine ravulisumaab on monoklonaalne antikeha (teatud valk), mis on välja töötatud seonduma C5-valguga (komplemendisüsteemi osa).
English: Ultomiris is a medicine used to treat adults with paroxysmal nocturnal haemoglobinuria (PNH).
Estonian: Ultomiris on ravim, mida kasutatakse paroksüsmaalse öise hemoglobinuuria raviks täiskasvanutel.
English: It should be used after patients have been treated with eculizumab (another medicine for PNH) for at least the past 6 months.
Estonian: Ultomirist tuleb kasutada pärast seda, kui patsiente on vähemalt viimase 6 kuu jooksul ravitud ekulisumaabiga (samuti paroksüsmaalse öise hemoglobinuuria ravim).
English: In PNH, proteins known as the 'complement system', which is part of the immune system, become overactive because of a genetic mutation and start to attack the patients' own red blood cells.
Estonian: Paroksüsmaalse öise hemoglobinuuria korral muutuvad komplemendisüsteemi (immuunsüsteemi osa) valgud geneetilise mutatsiooni tõttu liigaktiivseks ja ründavad patsientide erütrotsüüte.
English: Ultomiris is as effective as eculizumab in treating patients with PNH, reducing the breakdown of red blood cells and avoiding the need for transfusions.
Estonian: Ultomiris on paroksüsmaalse öise hemoglobinuuriaga patsientide ravis sama efektiivne kui ekulisumaab, vähendades erütrotsüütide lagunemist ja vereülekannete vajadust.
English: The medicine can only be obtained with a prescription and must be given under the supervision of a doctor who has experience in the management of patients with blood disorders.
Estonian: Ultomirise infusioon peab toimuda verehäiretega patsientide ravis kogenud arsti järelevalve all.
English: Ultomiris contains the active substance ravulizumab.
Estonian: Ultomiris sisaldab toimeainena ravulisumaabi.
English: Why is Ultomiris authorised in the EU?
Estonian: ELis Ultomirisele väljastatud müügiloa põhjendus
English: Date of first authorisation: 19 November 2015
Estonian: Müügiloa esmase väljastamise kuupäev: 19. november 2015
English: Tell your doctor if you are taking the following medicines.
Estonian: Öelge oma arstile, kui te võtate järgnevaid ravimeid.
English: The volume of distribution is high (approximately 1,000 litres), indicating extensive distribution.
Estonian: Jaotusruumala on suur (ligikaudu 1000 liitrit), mis viitab ulatuslikule jaotumisele.
English: Other pharmaceutical forms may be available for this population.
Estonian: Sellele populatsioonile võivad manustamiseks olla saadaval muud ravimvormid.
English: Please tell your doctor immediately:
Estonian: Teatage oma arstile kohe, kui:
English: 117 Allee des Parcs 69 800 Saint Priest France
Estonian: 117 Allée des Parcs 69 800 Saint Priest Prantsusmaa
English: Adults and elderly (> 65 years)
Estonian: Täiskasvanud ja vanurid (> 65 a)
English: Not known: frequency cannot be estimated from the available data
Estonian: Teadmata (sagedust ei saa hinnata olemasolevate andmete alusel):
English: * see section c) see section 4.4
Estonian: * vt lõik c) † vt lõik 4.4
English: For additional information see section 4.
Estonian: Täiendavat teavet vt lõik 4.
English: Hypocalcaemia (see sections 4.2 and 4.4).
Estonian: Hüpokaltseemia (vt lõigud 4.2 ja 4.4).
English: 4.8 Undesirable effects a)
Estonian: 4.8 Kõrvaltoimed a)
English: The normal calcium range may differ depending on the methods used by your local laboratory.
Estonian: Kaltsiumisisalduse normvahemik võib erineda, olenedes kohalikus laboris kasutatavast meetodist.
English: Children under the age of 18 must not take Cinacalcet Mylan.
Estonian: Lapsed ja noorukid Alla 18-aastased lapsed ei tohi Cinacalcet Mylan'it võtta.
English: • if you start or stop smoking, as this may affect the way Cinacalcet Mylan works.
Estonian: • kui te hakkate suitsetama või loobute suitsetamisest, sest see võib mõjutada Cinacalcet Mylan'i toimet.
English: Reduction of hypercalcaemia in patients with:
Estonian: Hüperkaltseemia vähendamine patsientidel, kellel on:
English: A population pharmacokinetic analysis was performed to evaluate the effects of demographic characteristics.
Estonian: Demograafiliste näitajate mõju hindamiseks tehti populatsiooni farmakokineetika analüüs.